INTRODUCTION {#S1}
============

Imaging the immune system in living subjects can define the spatiotemporal programming of innate and adaptive immunity. PET enables noninvasive, quantitative and tomographic assays of biological processes using molecular probes labeled with positron-emitting radioisotopes [@R1]. Studies in mice showed that PET is useful to visualize immune responses. Anti-tumor T cell responses can be monitored by PET reporter gene imaging [@R2]--[@R6]. Using a mouse model of autoimmune demyelination we showed that ^18^Fluorodeoxyglucose (\[^18^F\]FDG)[@R1] PET allows imaging of disease onset and of immunosuppressive therapy [@R7]. However, \[^18^F\]FDG accumulation in tissues like heart, brain and liver suggests the need for new PET probes with distinct biodistribution patterns. To develop such probes, we focused on the salvage pathway for DNA synthesis in which deoxyribonucleosides are converted to nucleotides by phosphorylation catalyzed by deoxyribonucleoside kinases (reviewed in [@R8]). While most tissues predominantly utilize the *de novo* pathway for DNA synthesis, lymphoid organs and rapidly proliferating tissues rely extensively on the salvage pathway [@R9]. To identify novel probes for the salvage pathway we: (*i*), *in vitro* screened nucleoside analogs for differential retention in proliferating and quiescent T cells; (*ii*), identified FAC, a new PET probe candidate with increased accumulation in proliferating T cells; (*iii*), performed gene expression and biochemical analyses to investigate the mechanism(s) of elevated FAC retention; (*iv*), radiochemically synthesized \[^18^F\]FAC for *in vivo* biodistribution studies; (*v*), compared \[^18^F\]FAC with PET probes currently used to measure nucleoside metabolism and glycolysis; and (*vi*), evaluated \[^18^F\]FAC in mouse models of immune activation. Similar strategies are broadly applicable to the development of new PET probes with specificity for various biochemical pathways and/or immune cell lineages. Our findings provide the impetus for clinical evaluation of \[^18^F\]FAC PET imaging in immune disorders and other diseases.

RESULTS {#S2}
=======

Differential screening to identify potential PET probes sensitive to changes in nucleoside flux associated with T cell activation and proliferation {#S3}
---------------------------------------------------------------------------------------------------------------------------------------------------

We measured the retention of \[^3^H\]-labeled deoxyribonucleoside analogs (NAs) in resting vs. proliferating primary CD8^+^T cells. Selection criteria for NAs accounted for the propensity of fluorine substitutions to change the biochemical properties of nucleosides (reviewed in [@R10]). Since fluorination at C-4′ is incompatible with ^18^F labeling and fluorination at C-5′ would prevent phosphorylation by nucleoside kinases, we tested only NAs containing 'cold' fluorine (^19^F) atom(s) substitutions at C-2′ or 3′ on the sugar moiety or at position 5 of the nucleobase ([Supplementary Fig. 1](#SD1){ref-type="supplementary-material"} online). [Fig. 1a](#F1){ref-type="fig"} shows a wide variation in NAs retention by quiescent and proliferating CD8^+^ T cells. While 2′,2′-difluorodeoxycytidine (dFdC) ([Fig. 1b](#F1){ref-type="fig"}) showed the best selectivity for proliferating cells, synthesis of ^18^F-labeled dFdC would be challenging. Precursors for \[^18^F\]dFdC are likely to be unstable because of the presence of the electronegative fluorine atom and an excellent leaving group at the C-2′ position. This and the need for large mass of precursor materials limit the specific activity of \[^18^F\]dFdC. To circumvent this problem we synthesized ^18^F labeled monofluorinated analogs of dFdC ([Supplementary Fig. 2](#SD1){ref-type="supplementary-material"} online). Relative to the stereochemical configurations of the C-2′ fluorine atom ([Fig. 1b](#F1){ref-type="fig"}), the F-*ara* ('up') analogs retain biological activity while the C-2′ *ribo* ('down') compounds are inactive (reviewed in [@R10]). Indeed, similar amounts of the F-*ara* analog 1-(2- deoxy-2-fluoro-arabinofuranosyl)-cytosine (FAC) ([Fig. 1b](#F1){ref-type="fig"}) and dFdC were retained in proliferating CD8^+^ T cells ([Fig. 1c](#F1){ref-type="fig"}). FAC retention in dividing T cells could reflect any one or combination of several biochemical events: (*i*), upregulation of nucleoside transporters; (*ii*), elevated phosphorylation by deoxyribonucleoside kinases; and, (*iii*), increased incorporation into the DNA. To determine expression of nucleoside transporters and kinases potentially involved in FAC retention we performed microarray and qPCR analyses. 2′-deoxycytidine (dCyd) analogs are transported by members of the solute carrier (SLC) families SLC28 (reviewed in [@R11]) and SLC29 (reviewed in [@R12]). *Slc29a1* expression was upregulated by \~4-fold in proliferating T cells vs. quiescent T cells while *Slc28a1* and *Slc28a3* [@R11] were not expressed (data not shown). Intracellular FAC could be phosphorylated and trapped by deoxycytidine kinase (dCK, *K*~cat~/*K*~m~ for dCyd = 2 × 10^5^) and by thymidine kinase 2 (TK2, *K*~cat~/*K*~m~ for dCyd = 3 x 10^4^) (reviewed in [@R13]). Following T cell activation, dCK mRNA levels increased by \~2-fold whereas TK2 expression decreased by \~5-fold (data not shown). Since SLC29A1 and dCK were previously involved in the metabolism of dFdC [@R14],[@R15], we further analyzed their role by overexpressing them in NIH3T3 fibroblasts. Thymidine kinase 1 (TK1, *K~cat~*/*K*~m~ for dCyd \<1 × 10^2^ [@R13]) was used as a negative control. \[^3^H\]FAC retention increased in both dCK^HIGH^ and SLC29A1^HIGH^ cells but not in TK1^HIGH^ cells which only accumulated \[^3^H\]fluorothymidine (FLT) ([Fig. 1d](#F1){ref-type="fig"}). To determine whether retention could also reflect DNA incorporation, T cells were activated for 72 hrs and then incubated for 1 to 8 hrs with \[^3^H\]FAC. The accumulation of \[^3^H\]FAC and \[^3^H\]dCyd (positive control) into DNA increased as a function of time ([Fig. 1e](#F1){ref-type="fig"}).

\[^18^F\]FAC has greater specificity for lymphoid organs than PET probes for nucleoside metabolism and glycolysis {#S4}
-----------------------------------------------------------------------------------------------------------------

Radiochemical synthesis of \[^18^F\]FAC ([Supplementary Fig. 2](#SD1){ref-type="supplementary-material"} online) reproducibly yielded a product with chemical and radiochemical purities greater than 99% and specific activity greater than 1 Ci/μmol. HPLC analysis of \[^18^F\]FAC up to 10 hrs post radiochemical synthesis did not detect products of radiolysis. Biodistribution, metabolism and clearance of \[^18^F\]FAC were studied in C57/BL6 mice. Tissue decay-corrected mean time-activity curves from dynamic \[^18^F\]FAC microPET/CT scans ([Supplementary Fig. 3a](#SD1){ref-type="supplementary-material"} online) suggested that \[^18^F\]FAC was predominantly cleared through kidney and liver ([Supplementary Fig. 3a,b](#SD1){ref-type="supplementary-material"} online). Imaging data were corroborated with radioactivity measurements in necropsy tissue samples ([Supplementary Fig. 3c](#SD1){ref-type="supplementary-material"} online) and with digital whole-body autoradiography (DWBA) ([Fig. 2a](#F2){ref-type="fig"}). One hour after injection of \[^18^F\]FAC, accumulated radioactivity was detected in thymus, spleen, intestine, bone/bone-marrow and liver. Similar to other deoxycytidine analogs, FAC is susceptible to deamination *in vivo* [@R16] ([Supplementary Fig. 4](#SD1){ref-type="supplementary-material"} online). Two lines of evidence suggest that the tissue accumulation of \[^18^F\]FAC is primarily regulated by dCK-mediated phosphorylation rather than by deamination. First, \[^18^F\]FAC and its phosphorylated derivatives was detected by HPLC analyses of thymic extracts. Second, biodistribution data indicated preferential retention of \[^18^F\]FAC in tissues with high dCK mRNA expression [@R13]. While further studies are required to precisely define biochemical mechanism(s) of retention, our data suggested that \[^18^F\]FAC enables visualization of cells with high deoxyribonucleoside salvage [@R9] such as lymphocytes, bone-marrow cells and enterocytes.

Compared with probes for nucleoside metabolism (\[^18^F\]FLT [@R17] and \[^18^F\]D-FMAU [@R18]) and glycolysis (\[^18^F\]FDG), \[^18^F\]FAC had a distinct biodistribution pattern ([Fig. 2c](#F2){ref-type="fig"}, [Table 1](#T1){ref-type="table"}, [Supplementary Fig. 5](#SD1){ref-type="supplementary-material"} online). \[^18^F\]FLT and \[^18^F\]D-FMAU showed no detectable accumulation in thymus and spleen while myocardial retention of \[^18^F\]FDG interferes with the thymus signal. To examine the cell lineage specificity of \[^18^F\]FAC resident populations from thymus and spleen were sorted using flow cytometry. While rapidly dividing double negative thymocytes had the highest retention of radioactivity, \[^18^F\]FAC also labeled peripheral T and B lymphocytes as well as CD11b^+^ myeloid cells ([Fig. 2d,e](#F2){ref-type="fig"}).

\[^18^F\]FAC microPET imaging of immune activation during a primary anti-tumor immune response {#S5}
----------------------------------------------------------------------------------------------

To determine whether \[^18^F\]FAC is sensitive to localized immune activation we used a onco-retrovirus tumor model [@R19] characterized by T cell priming by strong xenoantigens encoded by the *gag* and *env* genes of the Moloney murine sarcoma and leukemia virus complex (MoMSV). As shown using conventional *ex vivo* approaches [@R20] and PET reporter gene imaging [@R3],[@R6], non-metastatic MoMSV induced sarcomas are rejected in a T-cell dependent manner with reproducible kinetics. \[^18^F\]FAC scans at the peak of the anti-tumor immune response (Day 15) [Fig. 3a,b](#F3){ref-type="fig"}, [Supplementary Fig. 6](#SD1){ref-type="supplementary-material"} online) indicated increased accumulation in the spleen and tumor draining lymph nodes (DLNs) relative to Day -1 baseline scans. We then examined whether elevated retention of \[^18^F\]FAC at these sites reflects upregulated nucleoside salvage metabolism by activated CD8^+^ T cells. Splenic CD8^+^ T cells from mice injected with \[^18^F\]FAC were fractionated by flow cytometry into naïve (CD62L^HIGH^/CD44^LOW^) and effector populations (CD62L^LOW^/CD44^HIGH^). Effector CD8^+^ T cells retained \~4-fold more \[^18^F\]FAC than naïve T cells ([Fig. 3c](#F3){ref-type="fig"}).

To compare \[^18^F\]FAC with other probes MoMSV-challenged mice were scanned on consecutive days with \[^18^F\]FAC, \[^18^F\]FDG and \[^18^F\]FLT. On Day 13 post virus challenge, \[^18^F\]FDG accumulation was increased at the tumor site, tumor DLNs and spleen ([Fig. 3d](#F3){ref-type="fig"} and [Supplementary Fig. 6](#SD1){ref-type="supplementary-material"} online). Tumor lesions accumulated high amounts of \[^18^F\]FDG: 8.2 ±4.2 percent injected dose of activity per gram of tissue (%ID/g) of tumor over background (defined as the contralateral muscle tissue). In contrast, \[^18^F\]FAC retention in the tumor was lower (1.9 ±0.3 %ID/g). Although additional studies are required to elucidate whether \[^18^F\]FAC retention in tumors is due to infiltrating immune cells, preferential accumulation in the tumor DLNs (4.14 ±1.5 %ID/g) vs. tumor (1.9 ±0.3 %ID/g) ([Fig. 3a,d](#F3){ref-type="fig"}, [Supplementary Fig. 6](#SD1){ref-type="supplementary-material"} online) suggested that \[^18^F\]FAC has good specificity for imaging immune rejection of virally-induced sarcomas. In contrast to \[^18^F\]FAC, \[^18^F\]FLT did not accumulate at sites of immune activation ([Fig. 3e](#F3){ref-type="fig"}).

Disease and treatment evaluation using \[^18^F\]FAC PET in an animal model of systemic autoimmunity {#S6}
---------------------------------------------------------------------------------------------------

To determine whether \[^18^F\]FAC could allow monitoring of autoimmune disorders we used mice carrying the Fas*^lpr^* mutation. Deficient apoptosis of Fas*^lpr^* lymphocytes leads to lymphadenopathy, arthritis and immune complex-mediated glomerulonephrosis [@R21]. We used B6.MRL-*Fas^lpr^*/J mice which show slower disease progression than the MRL/Mp-*lpr/lpr* strain [@R22]. PET/CT scans of 2-3 month old B6.MRL-*Fas^lpr^*/J mice revealed increased numbers of \[^18^F\]FAC positive axillary and brachial lymph nodes (LNs) relative to age-matched wild type (WT) C57BL/6J controls ([Fig. 4](#F4){ref-type="fig"}, [Supplementary Fig. 7a](#SD1){ref-type="supplementary-material"} online). \[^18^F\]FAC positive LNs could be detected in 2 of 19 WT mice, whereas 9 of 13 *Fas^lpr^*/J mice showed signals indicative of lymphadenopathy. Quantification of \[^18^F\]FAC accumulation in LNs from *Fas^lpr^*/J mice showed an excellent correlation between retained radioactivity and T cell numbers ([Supplementary Fig. 7b](#SD1){ref-type="supplementary-material"} online). To determine whether \[^18^F\]FAC microPET/CT could monitor therapy, B6.MRL-*Fas^lpr^*/J mice were given dexamethasone (DEX), a synthetic glucocorticoid with potent immunosuppressive effects [@R23]. DEX had a profound effect on \[^18^F\]FAC retention in thymus and LNs presumably reflecting the cytotoxic effects of this drug towards lymphocytes ([Fig. 4](#F4){ref-type="fig"}, [Supplementary Fig. 7a](#SD1){ref-type="supplementary-material"} online).

DISCUSSION {#S7}
==========

A new PET probe for imaging the immune system {#S8}
---------------------------------------------

\[^18^F\]FAC is a novel PET probe which allows visualization of thymus and spleen in mice and is sensitive to alterations in lymphoid mass and immune status. Current results and our previous \[^18^F\]FDG PET imaging study in Experimental Autoimmune Encephalomyelitis (EAE)[@R7] indicate that \[^18^F\]FAC and \[^18^F\]FDG can be used to measure key metabolic pathways in immune cells. While these probes are not absolutely specific for immune cells, changes in their accumulation throughout the body could be indicative of "disease states" and could provide early biomarkers. Direct comparisons of \[^18^F\]FAC with \[^18^F\]FDG and \[^18^F\]FLT indicate that \[^18^F\]FAC has better selectivity for lymphoid organs such as thymus, spleen and lymph nodes. Potential disadvantages of \[^18^F\]FAC include its baseline retention in lymphoid organs which could hamper the detection of weak immune responses at these sites and relatively high retention in the small and large intestine.

\[^18^F\]FAC as a cancer imaging probe {#S9}
--------------------------------------

Dysregulated nucleoside metabolism represents a hallmark of cancer and preliminary results indicate that \[^18^F\]FAC could be useful in oncology imaging. We evaluated \[^18^F\]FAC in several tumor models ([Supplementary Fig. 8](#SD1){ref-type="supplementary-material"} online). Increased \[^18^F\]FAC retention in the spleen was observed in leukemia induced by transplantation of Bcr-Abl transformed Ba/F3 cells or bone marrow cells. \[^18^F\]FAC PET visualized tumors induced by murine B16 cells (representative of malignant melanoma) and human U87 cells (representative of glioma tumors). Future studies are warranted to directly compare \[^18^F\]FAC with \[^18^F\]FDG and \[^18^F\]FLT for detection of various cancers. Furthermore, \[^18^F\]FAC PET could enable prediction of tumor responses to a class of anticancer agents represented by structurally related prodrugs cytarabine (Ara-C) and 2′-difluorodeoxycytidine (dFdC, Gemcitabine). Similar to FAC retention, the activation of these widely used prodrugs requires uptake via similar nucleoside transporters and dCK-mediated phosphorylation (reviewed in [@R13]).

In conclusion, \[^18^F\]FAC PET imaging could offer new insights for diagnostics and treatment monitoring of a wide range of disorders. Studies are underway to translate \[^18^F\]FAC PET imaging to the clinic and evaluate its potential for monitoring autoimmunity, inflammation and cancer.

METHODS {#S10}
=======

\[^3^H\]-labeled nucleosides (see also [Supplementary Fig. 1](#SD1){ref-type="supplementary-material"}) {#S11}
-------------------------------------------------------------------------------------------------------

The following tritium labeled nucleosides were purchased from Moravek Biochemicals (Brea, CA): 3′ Fluoro 3′ deoxythymidine (3′FLT); 2′ Fluoro 2′ deoxy-Thymidine (2′FLT); 1-(2-Deoxy-2-Fluoro-B-D-arabino-furanosyl)-5-methyluracil (D-FMAU); 1-(2-Deoxy-2-Fluoro-B-L-arabinofuranosyl) 5 methyluracil (L-FMAU); 2,3-dideoxy-3-fluorocytidine (3′FddC); (-)-β-2,3-Dideoxy-5-fluoro-3-thiacytidine (FTC); 5-Fluoro-2,3-dideoxycytidine (5FddC); 2′,2′-Difluorodeoxycytidine (dFdC); 5-Fluoro-2′-Deoxycytidine (5FdC); 5-Fluoro-2-deoxyuridine (5FdURD); 2′-Fluoro-2-deoxyuridine (2FdUrd); 1-(2-deoxy-2-fluoro-B-D-arabinofuranosyl)-uracil (FAU); 2′-Fluoro-2′-deoxy5-Fluorouracil-β-D---arabino-furanoside (FFAU).

T cell activation and radioactive tracer uptake assay {#S12}
-----------------------------------------------------

T lymphocytes from pmel-1 T cell receptor (TCR) transgenic mice [@R24] were stimulated *ex vivo* using their cognate antigen (1 μM hgp100~25--33~) and cultured for 72 hrs. For radioactive tracer uptake assays, 1 μCi of \[^3^H\]FAC or \[^3^H\]dFdC were added to wells containing 5x10^4^ cells in a 96-well tissue culture plate and incubated for 1 hr at 37^o^C and 5% CO~2~. The plate was washed five times with media containing 5% fetal calf serum using the Millipore Vacuum Manifold (Billerica, MA). The amount of incorporated probe was measured by scintillation counting using the PerkinElmer Microbeta (Waltham, MA). DNA incorporation assays using \[^3^H\]-labeled nucleosides were performed as previously described [@R25].

Radiochemical synthesis of ^18^F-labeled PET probes {#S13}
---------------------------------------------------

The radiochemical synthesis of \[^18^F\]FAC is described in [Supplementary Fig. 2](#SD1){ref-type="supplementary-material"} online. The radiochemical synthesis of \[^18^F\]FDG [@R26], \[^18^F\]FLT [@R17], and \[^18^F\]D-FMAU [@R27] was performed as previously described.

MicroPET/CT imaging {#S14}
-------------------

Mice were kept warm under gas anesthesia (2% isoflurane) and injected with 200 μCi of various PET probes i.v. and allowed 1 hr uptake. Mice were then positioned using an imaging chamber. Data were acquired using Siemens Preclinical Solutions (Knoxville, TN) microPET Focus 220 and MicroCAT II CT systems. MicroPET data were acquired for 10 minutes and reconstructed using a statistical maximum a posteriori probability algorithm (MAP) [@R28] into multiple frames. The spatial resolution of PET is \~1.5 mm, 0.4 mm voxel size. CT images are a low dose 400 μm resolution acquisition with 200 μm voxel size. MicroPET and CT images were co-registered as previously described [@R29]. Quantification was performed by drawing 3D regions of interest (ROI) using the AMIDE software [@R30]. Color scale is proportional to tissue concentration with red being the highest and lower values in yellow, green & blue.

Animal models for immune activation {#S15}
-----------------------------------

Mice used in these studies were bred and maintained according to the guidelines of the Department of Laboratory Animal Medicine (DLAM) at the University of California, Los Angeles. The MoMSV sarcoma model was described previously [@R3]. B6.MRL-Fas^lpr^/J mice used for systemic autoimmunity studies were purchased from The Jackson Laboratory (stock number: 000482). Dexamethasone (DEX, 10 mg/kg) was administered by intraperitoneal injections in 100 μL PBS at 24 hr intervals for 2-7 days. Mice were scanned by microPET/CT 24 hr after the last injection.

Digital whole-body autoradiography {#S16}
----------------------------------

Mice were anesthetized with 2% isoflurane and were injected i.v. with 1mCi \[^18^F\]FAC. The DWBA was performed by using previously described methods [@R7]. Frozen coronal whole body mouse sections (45 μm thick) were exposed overnight and were developed using a Fuji BAS 5000 Imager at 100 μm spatial resolution.

Data presentation and statistical analysis {#S17}
------------------------------------------

Graphs were constructed using GraphPad Prism software, version 4.02. *P* values were calculated using Student's *t* test. *P* values of \<0.05 were considered significant. Data are presented as means ± standard errors of the mean (SEM).
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![Identification of fluorinated deoxycytidine analogs retained in activated vs. naïve T cells\
**(a)** Primary CD8^+^ T cells were stimulated *ex vivo* for 72 hrs and then were incubated for 1 hr with \[^3^H\]-labeled NAs; following successive washes, intracellular radioactivity was measured by scintillation counting. **(b)** FAC is a dFdC analog amenable to ^18^F labeling. **(c)** Similar retention of \[^3^H\]dFdC and \[^3^H\]FAC by activated mouse CD8+ T cells; the retention of \[^3^H\]FAC in naïve CD8+ T cells was 18+/−4.5 fmoles/10^5^ cells **(d)** Increased uptake of \[^3^H\]FAC in NIH3T3 fibroblasts engineered to overexpress nucleoside kinases (dCK, TK1) and the nucleoside transporter SLC29A1. \[^3^H\]FLT was used as a positive control for TK1 expressing cells. **(e)** \[^3^H\]FAC and the parental nucleoside 2′ deoxycytidine (\[^3^H\]dCyd, used as a positive control) are incorporated in the DNA of proliferating CD8+ T cells as a function of time (see text for details). \* *P* values of \<0.05. Results are representative of two independent experiments.](nihms127468f1){#F1}

![\[^18^F\]FAC has better selectivity for lymphoid organs compared with other PET probes for nucleoside metabolism and glycolysis\
**(a)** \[^18^F\]FAC DWBA shown along with the corresponding tissue sections. **(b,c)** C57/BL6 mice were scanned by microPET/CT using \[^18^F\]FAC, \[^18^F\]FLT, \[^18^F\]D-FMAU and \[^18^F\]FDG. Mice were imaged 60 min after i.v. injection of probes. The orientation of saggital, coronal and transverse sections is depicted in the 3D microCT image in panel **b**. Images are 1 mm thick sagittal, coronal and transverse slices. Percent ID/g, percent injected dose per gram of tissue; B, Bone; BL, Bladder; BR, Brain; GB, Gall Bladder; GI, Gastrointestinal tract; H, heart; K, Kidney; L, Liver; LU, Lung; SP, Spleen; Thy, thymus; BM, bone marrow; ST, stomach. **(d)** \[^18^F\]FAC retention/cell number in thymocytes and splenocytes. **(d)** Proportion of \[^18^F\]FAC retention/cell lineage per lymphoid organ (see text for details).](nihms127468f2){#F2}

![Increased \[^18^F\]FAC retention in spleen and lymph nodes at the peak of the primary anti-tumor immune response\
Images are 1 mm coronal sections from microPET/CT scans using \[^18^F\]FAC (Day -1 and Day 15, panel **a**), \[^18^F\]FDG (Day 13, panel **d**) and \[^18^F\]FLT (Day 14, panel **e**). B, Bone; BL, Bladder; GI, Gastrointestinal tract; H, heart; SP, Spleen; TU, tumor; Thy, thymus; LN, lymph node. **(b)** Quantification of \[^18^F\]FAC retention in spleen and lymph nodes on Day -1 and Day 15; Number of mice =3. **(c)** Increased *in vivo* accumulation of \[^18^F\]FAC in effector CD8+ T cells vs. naïve CD8+ T cells. Mice were challenged with the MoMSV onco-retrovirus and 14 days later were injected with 1 mCi \[^18^F\]FAC. Following 1 hr *in vivo* uptake, mice were sacrificed to isolate splenocytes which were fractionated by flow cytometry into naïve CD8^+^ T cells (CD44^LOW^/CD62L^HIGH^) and effector CD8^+^ T cells (CD44^HIGH^/CD62L^LOW^). Radioactivity accumulated by these cells was measured using a well counter. Results are representative of two independent experiments.](nihms127468f3){#F3}

![\[^18^F\]FAC microPET/CT allows visualization of increased lymphoid mass in systemic autoimmunity and can be used to monitor immunosuppressive therapeutic interventions\
Images are 60 minutes after i.v. injection of \[^18^F\]FAC and show three 1 mm thick coronal slices from (**a**) wild-type (C57BL/6J) and B6.MRL-*Fas^lpr^*/J (**b**) before and (**c**) after treatment with DEX. \[^18^F\]FAC positive LNs were scored blindly. Thy, thymus; LN, lymph nodes; BM, bone-marrow. Results are representative of two independent experiments.](nihms127468f4){#F4}

###### 

Amongst existing PET probes for nucleoside metabolic pathways and glycolysis, \[^18^F\]FAC shows better selectivity for thymus and spleen (values are %ID/g per organ normalized to %ID/g muscle). Retention of \[^18^F\]FDG in the thymus could not be measured because of signal spillover from the heart. Number of mice = 3.

               \[^18^F\]FAC   \[^18^F\]FLT   \[^18^F\]FMAU   \[^18^F\]FDG
  ------------ -------------- -------------- --------------- --------------
  **Spleen**   2.16+/− 0.48   1.02+/− 0.21   1.08+/− 0.27    1.69+/− 0.16
  **Thymus**   3.29+/− 0.48   1.22+/− 0.23   1.33+/− 0.24    N.D.
